First-in-Human trial tests novel 'Messenger' therapy for tough blood cancers
NCT ID NCT07240974
Summary
This is a very early study to test the safety and initial effects of a new experimental treatment called ZZSW-01 for adults with advanced B-cell blood cancers that have come back or not responded to standard therapies. The treatment involves giving patients modified immune cells designed to target and fight their cancer. The main goal is to find a safe dose and see if the body tolerates the treatment, while also checking for any early signs that it might help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, 430022, China
Conditions
Explore the condition pages connected to this study.